Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher's NSCLC Companion Dx Covered by Regence BCBS

UPDATE: The story had incorrectly stated that the test was FDA approved as a companion diagnostic to identify patients with ALK mutations who may respond to the cancer drug Xalkori. We regret the error.

NEW YORK (GenomeWeb) – Thermo Fisher Scientific today said its Oncomine Dx Target Test has received a positive coverage decision from Regence Blue Cross Blue Shield.

As a result, the insurer will cover the test for its members with non-small cell lung cancer in Oregon, Idaho, Utah, and certain counties in Washington.

The next-generation sequencing-based companion diagnostic, which simultaneously evaluates 23 genes clinically associated with NSCLC, allows physicians to match patients to therapies, which have been approved by the US Food and Drug Administration, in days instead of weeks, Thermo Fisher said.

The FDA approved the panel in June to predict which patients with EGFR mutations, ROS1 rearrangements, and BRAF mutations are likely to derive benefit from Iressa (gefitinib), Xalkori (crizotinib), and the Mekinist (trametinib)/Tafinlar (dabrafenib) combo, respectively. In August, the test received a proprietary laboratory analyses code from the American Medical Association, Thermo Fisher said. 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more